Slide 1: Takeda's Commitment to Inclusive and Equitable Clinical Research in Psoriasis
TAKEDA’S COMMITMENT TO INCLUSIVE AND EQUITABLE CLINICAL RESEARCH IN PSORIASIS More than 7.5 million Americans and 60 million’ people worldwide live with psoriasis, a chronic, immune-mediated inflammatory disease that leads to the development of thick, scaly plaques on the skin." PSORIASIS IS ASSOCIA
Slide 2: An Additional Challenge of Epidemiology Data
AN ADDITIONAL CHALLENGE OF EPIDEMIOLOGY DA “A clear understanding of the global burden of psoriasis begins with comprehensive prevalence data from as many countries as possible. We are collaborating with like-minded organizations to build a strong evidence base, track comorbidities, assess the econo
Slide 3: Progress against enrollment goals in Phase 3 psoriasis trials
Our team incorporated our tested strategy to the way to clinical trials that better represent real-world patient populations. We actively tracked our progress and pivoted as needed, striving to meet our goals without slowing down enrollment. We are proud we were able to meet or exceed nearly all of
Slide 4: References
REFERENCES Dhabale A, Nagpure S. Types of psoriasis and their effects on the immune system. Cureus. 2022; 24;14(9):e29536. doi: 10.7759/cureus.20536. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, & Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA dermatology. 2021;157